Stay updated on Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check44 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check52 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check66 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check73 days agoChange DetectedThe website has added a new version (v2.14.0) of the 'type of intervention' feature, replacing the previous version (v2.13.3) that was removed.SummaryDifference2%
- Check102 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
Stay in the know with updates to Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.